Indian Journal of Hematology and Blood Transfusion最新文献_第5页

A Retrospective Cohort Study to Evaluate the Outcomes of HIV-Associated High-Grade B-Cell Non-Hodgkin Lymphoma (NHL) Treated with Dose Adjusted EPOCH (+/-R) Regimen. 一项回顾性队列研究评估剂量调整EPOCH(+/−R)方案治疗hiv相关高级别b细胞非霍奇金淋巴瘤(NHL)的结果

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-01-01 Epub Date: 2023-04-21 DOI: 10.1007/s12288-023-01652-3

Jayashree Thorat, Manju Sengar, Raajit Chanana, Akhil Kapoor, Ajay Singh, Avinash Bonda, Hari Menon, Bhausaheb Bagal, Siddharth Laskar, Nehal Khanna, Jayant Shastri Goda, Epari Sridhar, Sumeet Gujral, Archi Agarwal, Sheela Sawant, Anuprita Daddi, Tanuja Shet, Netra Ghandade, Hasmukh Jain

{"title":"A Retrospective Cohort Study to Evaluate the Outcomes of HIV-Associated High-Grade B-Cell Non-Hodgkin Lymphoma (NHL) Treated with Dose Adjusted EPOCH (+/-R) Regimen.","authors":"Jayashree Thorat, Manju Sengar, Raajit Chanana, Akhil Kapoor, Ajay Singh, Avinash Bonda, Hari Menon, Bhausaheb Bagal, Siddharth Laskar, Nehal Khanna, Jayant Shastri Goda, Epari Sridhar, Sumeet Gujral, Archi Agarwal, Sheela Sawant, Anuprita Daddi, Tanuja Shet, Netra Ghandade, Hasmukh Jain","doi":"10.1007/s12288-023-01652-3","DOIUrl":"10.1007/s12288-023-01652-3","url":null,"abstract":"High-grade B-cell NHL's are more common in seropositive patients. They are biologically different from their seronegative counterparts. We report our analysis on our cohort of patients who were treated with DA-EPOCH(+/-R). We retrospectively analyzed treatment-naïve HIV-associated High-grade B-cell NHL patients (aged ≥ 18) treated with DA-EPOCH(+/-R) regimen from 2011 to 2015. Descriptive statistics were summarized with median and range; survival outcomes were analyzed with Kaplan-Meier method. The cohort comprised of 40 patients [DLBCL(19), Burkitt's Lymphoma(16), High-grade B-Cell Lymphoma-Unclassifiable(09), and Plasmablastic Lymphoma(01)] and the median CD4 + T cell count was 202/mm3. CNS prophylaxis was administered with intrathecal methotrexate to 90% of patients. With a median follow-up of 72 months, an estimated 5-year OS was 82.5%, and 5-PFS was 77.5%. There were 9 deaths, and 9 patients had progression. At least 4 cycles of chemotherapy were administered to 35 (93%) patients, with 28 (70%) receiving 6 cycles. Grade 3-4 toxicities were seen in 33 (83%) patients- febrile neutropenia (65%) being the most common followed by mucositis (25%) and peripheral neuropathy (13%). There was no difference in survival based on IPI, CD 4 + T cell count, CDI, or duration of HIV. DA-EPOCH(+/-R) is a highly effective regimen in seropositive high-grade B-cell lymphoma, even in the presence of adverse features.Supplementary information: The online version contains supplementary material available at 10.1007/s12288-023-01652-3.","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10830987/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44675970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cytomegalovirus Reactivation as a Risk Factor for All-Cause Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation: Experience Over Two Decades from a Tertiary Referral Center in India. 巨细胞病毒反应是接受造血干细胞移植的儿童全因死亡的危险因素：印度三级转诊中心20多年的经验

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-01-01 Epub Date: 2023-04-17 DOI: 10.1007/s12288-023-01654-1

Sohini Chakraborty, Venkateswaran Vellaichamy Swaminathan, Kavitha Ganesan, Suresh Duraisamy, Satishkumar Meena, Indira Jayakumar, Vidya Krishna, Ramya Uppuluri, Revathi Raj

{"title":"Cytomegalovirus Reactivation as a Risk Factor for All-Cause Mortality in Children Undergoing Hematopoietic Stem Cell Transplantation: Experience Over Two Decades from a Tertiary Referral Center in India.","authors":"Sohini Chakraborty, Venkateswaran Vellaichamy Swaminathan, Kavitha Ganesan, Suresh Duraisamy, Satishkumar Meena, Indira Jayakumar, Vidya Krishna, Ramya Uppuluri, Revathi Raj","doi":"10.1007/s12288-023-01654-1","DOIUrl":"10.1007/s12288-023-01654-1","url":null,"abstract":"The aim of the study was to analyse the burden of cytomegalovirus (CMV) disease in children undergoing hematopoietic stem cell transplantation (HSCT) and its correlation with all-cause mortality. We performed a retrospective study in children up to 18 years of age who underwent allogeneic HSCT between February 2002 to December 2021 in the pediatric blood and marrow transplantation unit. A total of 1035 patients were included where five hundred forty-three (52.4%) patients underwent matched family donor (MFD) HSCT, 213 (20.5%) underwent matched unrelated donor (MUD) HSCT; 279 (26.9%) underwent haploidentical HSCT (T cell replete in 213 and T cell depleted in 66 patients). CMV reactivation was documented in 258 (24.9% patients). CMV was seen in 39 (7.2%) MFD, 77 (36.1%) MUD, 106 T cell replete (49.7%) and 36 T cell depleted (54.5%) transplants. CMV reactivation was predominantly documented in those where donor and recipient were positive (D + /R +) for CMV serostatus (77%)) prior to HSCT. Overall mortality rate was significantly higher in the CMV positive group (103/258, 39.9%), as compared to the CMV negative group (152/777, 19.6%) (p value = 0.0001). CMV was the direct cause of death in 13/1035 children (1.2%). GvHD as a cause of death was found to be significantly higher among those with CMV (n = 32) as compared to those without CMV (n = 14) (35.6 versus 9%, p value = 0.0001). The incidence of CMV reactivation was noted in 25% of HSCT recipients, and predominantly in haploidentical HSCTs. CMV reactivation was shown to significantly impact all-cause mortality and there was a significantly increased risk of mortality due to GvHD among those with CMV reactivation.","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10831035/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44995638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hemoglobin Shimonoseki HBA1:c.164A > G Illustrating the Continuing Utility of the Sickling Test and the Challenges in Antenatal Genetic Counselling. 下关血红蛋白HBA1:c.164A > G说明唾液测试的持续效用和产前遗传咨询的挑战

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-01-01 Epub Date: 2023-05-11 DOI: 10.1007/s12288-023-01670-1

Prashant Sharma, Prateek Bhatia, Reena Das, Sanjeev Chhabra, Jasbir Kaur Hira

引用次数: 0

Planning and designing of an inpatient isolation facility for hematopoietic stem cell transplant patients. 造血干细胞移植患者住院隔离设施的规划与设计

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-01-01 Epub Date: 2023-03-29 DOI: 10.1007/s12288-023-01647-0

Vijaydeep Siddharth, Tilotma Jamwal, Mukul Aggarwal, Sidhartha Satpathy, D K Sharma, Manoranjan Mahapatra

{"title":"Planning and designing of an inpatient isolation facility for hematopoietic stem cell transplant patients.","authors":"Vijaydeep Siddharth, Tilotma Jamwal, Mukul Aggarwal, Sidhartha Satpathy, D K Sharma, Manoranjan Mahapatra","doi":"10.1007/s12288-023-01647-0","DOIUrl":"10.1007/s12288-023-01647-0","url":null,"abstract":"During the last two decades the world has seen an increase in the use of Hematopoietic Stem Cell Transplant (HSCT) which has led to its worldwide expansion. Since, HSCT unit is an advanced set up, developing and maintaining a successful hematopoietic stem cell transplant program with a properly functioning unit enhances the credibility of any tertiary level medical facility especially for a country like ours which is in its early expanding phase of providing transplant services. The underlying principle for designing any HSCT facility is to maintain the highest possible level of aseptic environment for patients undergoing the transplant in order to prevent healthcare associated infections. Basic premises of designing the entire HSCT unit was to ensure restricted access to the facility and having an aseptic environment by implementing infection control parameters in design elements, which are explained subsequently in the article. The present manuscript describes the project experience of creating a positive pressure isolation facility for HSCT patients at a tertiary care hospital, India, which is a resource limited setting with an emphasis on need assessment, key elements in planning and designing along with the challenges associated with it.","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10831010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45757919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CMV Infection Post Allogeneic Hematopoietic Stem Cell Transplantation in a Resource Limited Country. 资源有限国家同种异体造血干细胞移植后巨细胞病毒感染

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-01-01 Epub Date: 2023-04-20 DOI: 10.1007/s12288-023-01655-0

Noor Yuhyi Sulaiman, Nur Adila Anuar, Normala Arshad, Chin Sum Cheong, Chee Chiat Liong, Shasha Khairullah, Edmund Fui Min Chin, Ping Chong Bee, I Ching Sam, Thevambiga Iyadorai, Gin Gin Gan

{"title":"CMV Infection Post Allogeneic Hematopoietic Stem Cell Transplantation in a Resource Limited Country.","authors":"Noor Yuhyi Sulaiman, Nur Adila Anuar, Normala Arshad, Chin Sum Cheong, Chee Chiat Liong, Shasha Khairullah, Edmund Fui Min Chin, Ping Chong Bee, I Ching Sam, Thevambiga Iyadorai, Gin Gin Gan","doi":"10.1007/s12288-023-01655-0","DOIUrl":"10.1007/s12288-023-01655-0","url":null,"abstract":"Cytomegalovirus (CMV) infection is one of the common complications which can lead to significant morbidity and mortality in patients after allogeneic hematopoietic stem cell transplantation (HSCT). As the seroprevalence of CMV infection in Malaysia is high, this study aims to determine the prevalence of CMV infection in patients post HSCT and to evaluate the associated risk factors. Patients who underwent allogeneic HSCT in adult ward from 2008 to 2020 at a tertiary teaching hospital in Kuala Lumpur, Malaysia were studied retrospectively. They were followed up for a minimum of 100 days post-HSCT to determine the incidence of CMV infection. CMV infection was defined according to CMV Drug Development Forum 2014. Risk factors such as type of transplant, serostatus of donor and patients, age, gender, race, presence of graft versus host disease (GVHD) and underlying disease were included for analysis. A total of 112 patients were included. Forty (35.7%) patients had CMV infection with median of onset recorded as 40 days (range 13-95 days). Only haplo-identical HSCT and presence of GVHD were identified as significant risk factors. Patients who had CMV infection had a lower median survival time although this was not statistically significant. The CMV infection rate was comparable with previous reports in Asia and as expected, higher than the western countries. Therefore, vigilant monitoring of CMV infection should be implemented especially in patients who had haplo-identical HSCT and acute GVHD.","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10830936/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42068899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CG02N Analyzer Accurately Measures Fibrinogen Level in Whole Blood in the Presence of Low- or High-Dose Heparin. CG02N分析仪在低剂量或高剂量肝素存在下准确测量全血纤维蛋白原水平

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2024-01-01 Epub Date: 2023-05-02 DOI: 10.1007/s12288-023-01659-w

Yoshihiko Nakamura, Junichi Maruyama, Takehiro Umemura, Kota Hoshino, Yuhei Irie, Shinichi Morimoto, Yoshito Izutani, Hiroyasu Ishikura

{"title":"CG02N Analyzer Accurately Measures Fibrinogen Level in Whole Blood in the Presence of Low- or High-Dose Heparin.","authors":"Yoshihiko Nakamura, Junichi Maruyama, Takehiro Umemura, Kota Hoshino, Yuhei Irie, Shinichi Morimoto, Yoshito Izutani, Hiroyasu Ishikura","doi":"10.1007/s12288-023-01659-w","DOIUrl":"10.1007/s12288-023-01659-w","url":null,"abstract":"Rapid fibrinogen (Fbg) evaluation is important in patients with massive bleeding during severe trauma and those undergoing major surgery. However, there are only a few studies on the point-of-care Fbg analyzer. In this study, we aimed to investigate the accuracy of Fbg level measured using CG02N, with whole blood contained in lithium-heparinized syringes with two different concentrations of heparin. Blood samples were collected in lithium-heparinized tubes, namely PREZA-PAK®II (low-dose heparin group [LG], 7 IU/mL) and Pro-Vent® Plus (high-dose heparin group [HG], 70.5 IU/mL). The Fbg levels in LG and HG were compared with those of citrated plasma Fbg (standard-Fbg). Strong correlations with respect to the Fbg level were observed between standard-Fbg and LG or HG (r = 0.968, p < 0.0001; r = 0.970, p < 0.0001, respectively). We demonstrated that the Fbg level in whole-blood samples was accurately assessed by CG02N and not affected by low- or high-dose heparin.","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10831028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45571798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AML With HIV Infection in The Era of Precision Oncology – Do We See The Light At The End of The Tunnel? 精准肿瘤学时代感染艾滋病毒的急性髓细胞白血病--我们看到隧道尽头的曙光了吗？

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2023-12-08 DOI: 10.1007/s12288-023-01715-5

S. Mailankody, Ananth Pai, Ram Bhat, Karthik Udupa

引用次数: 0

Biclonal Low-Grade B Cell Lymphoma as Detected by Multiparametric Flow Cytometry in Blood and Marrow. 血液和骨髓多参数流式细胞术检测双克隆低级别B细胞淋巴瘤。

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2023-10-01 Epub Date: 2023-01-02 DOI: 10.1007/s12288-022-01625-y

Thulasi Raman Ramalingam, Srikanth Muralikrishnan, Jose Easow, Lakshman Vaidhyanathan

{"title":"Biclonal Low-Grade B Cell Lymphoma as Detected by Multiparametric Flow Cytometry in Blood and Marrow.","authors":"Thulasi Raman Ramalingam, Srikanth Muralikrishnan, Jose Easow, Lakshman Vaidhyanathan","doi":"10.1007/s12288-022-01625-y","DOIUrl":"https://doi.org/10.1007/s12288-022-01625-y","url":null,"abstract":"Biclonal B cell lymphomas (BCL) of two different low-grade components are rare. Multiparametric flow cytometry (MFC) is an integral tool in lymphoma diagnosis and very efficient in picking up BCL cases, especially when the associated second component is small. We studied the incidence of BCL in the routine blood and marrow samples sent for immunophenotyping by MFC. A total of 376 cases were analyzed retrospectively. We studied their clinical, immunophenotypic, molecular, and cytogenetic findings with literature review. We found five cases of BCL with two different clonal low-grade B cell components at an incidence of 1.3%. All cases were males with a median age of 68 years. The chronic lymphocytic leukemia (CLL) clone was present in all 5 cases. The other associated component in cases 1 to 5 were lymphoplasmacytic lymphoma, follicular lymphoma, splenic marginal zone lymphoma, hairy cell leukemia, and monoclonal B cell population of non-CLL type respectively. Diagnosing BCL may be challenging and may also go undiagnosed when the second component is petite and overshadowed by the more significant component. It may be critical if the small, unnoticed lymphoma component is of a more aggressive type.Supplementary information: The online version contains supplementary material available at 10.1007/s12288-022-01625-y.","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41167397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effective and Elaborative Induction Program for Mitigating Myths and Misconceptions Linked to Hematopoietic Stem Cell Transplantation in a Resource Limited Setting. 在资源有限的环境中缓解与造血干细胞移植相关的神话和误解的有效和精细的诱导计划。

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2023-10-01 Epub Date: 2023-03-16 DOI: 10.1007/s12288-023-01634-5

Safaa A A Khaled, Mahmoud M Elzembely, Asmaa M A Soliman, Nahed Shwakat, Nashwa Rafaat, Mohamed A Malek, Esmat S Abdelmageed

{"title":"Effective and Elaborative Induction Program for Mitigating Myths and Misconceptions Linked to Hematopoietic Stem Cell Transplantation in a Resource Limited Setting.","authors":"Safaa A A Khaled, Mahmoud M Elzembely, Asmaa M A Soliman, Nahed Shwakat, Nashwa Rafaat, Mohamed A Malek, Esmat S Abdelmageed","doi":"10.1007/s12288-023-01634-5","DOIUrl":"https://doi.org/10.1007/s12288-023-01634-5","url":null,"abstract":"Since the first transplant in 1957 and hematopoietic stem cell transplantation (HSCT) is the curative modality for numerous hematological disorders. Nevertheless, it is not available for all patients. Besides unavailability of matched donors a lot of factors could hinder HSCT in a resource limited setting, as financial and administrative factors. In our daily practice we noticed other factors that hinder HSCT in our center, the common myths and misconceptions about HSCT and donation. This quasi-experimental study assessed, for the first time, common myths and misconceptions about HSCT among 218 medical and nursing students before and after an interventional educational program. The study tool was an investigators' developed self-administered questionnaire. Participants' male to female ratio was 1:2.5, and FAS was middle in 52.7%. Pretest high myths scores were reported in 53.4% and 90% of medical and nursing students that was reduced to 0% and 4% post-test, respectively. Pretest, 26.3% and 7% of medical and nursing students welling to donate HSC, that increased to 66% and 39% post-test, respectively. Rural residency, low and middle FAS associated with higher myths scores. Myths score is an independent effector of willingness to donate HSC among participants. In conclusion medical/nursing students had significant myths and misconceptions about HSCT that was corrected with the educational program. Thus, wide based educational programs about HSCT are mandatory to correct myths and augment HSC donation. www.clinicaltrrial.gov: clinical trial ID NCT05151406.Supplementary information: The online version contains supplementary material available at 10.1007/s12288-023-01634-5.","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41122486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

In-vitro Modulation of mTOR-HIF-1α Axis by TLR7/8 Agonist (Resiquimod) in B-Chronic Lymphocytic Leukemia. TLR7/8激动剂（雷喹莫特）对慢性B淋巴细胞白血病mTOR-HIF-1α轴的体外调节作用。

IF 0.9 4区医学

Indian Journal of Hematology and Blood Transfusion Pub Date : 2023-10-01 Epub Date: 2023-04-07 DOI: 10.1007/s12288-023-01649-y

Rana M Hanafy, Soheir R Demian, Lobna A Abou-Shamaa, O Ghallab, Eman M Osman

{"title":"In-vitro Modulation of mTOR-HIF-1α Axis by TLR7/8 Agonist (Resiquimod) in B-Chronic Lymphocytic Leukemia.","authors":"Rana M Hanafy, Soheir R Demian, Lobna A Abou-Shamaa, O Ghallab, Eman M Osman","doi":"10.1007/s12288-023-01649-y","DOIUrl":"https://doi.org/10.1007/s12288-023-01649-y","url":null,"abstract":"Targeting toll-like receptors (TLRs), via TLR agonists, has been implicated in the regulation of immunometabolism. B-chronic lymphocytic leukemia (B-CLL) represents a suitable model for B-cell derived malignancies with shifted metabolic adaptations. Several signaling pathways have been found to be critical in metabolic reprogramming of CLL, including mechanistic target of rapamycin- hypoxia inducible factor-1α (mTOR- HIF-1α) pathway, the main metabolic regulator of glycolysis. Here, we investigated the effect of TLR7/8 agonist (Resiquimod) on the expression of mTOR and HIF-1α in patients with CLL. B cells were purified using Rosettesep Human B cell Enrichment Cocktail (Stem cell Technologies, Vancouver, BC, Canada#15,024) from peripheral venous blood of CLL patients (n = 20) and healthy individuals (n = 15). Isolated B cells were then cultured in both presence and absence of Resiquimod. Gene expression of mTOR and HIF-1α were assessed using qRT-PCR. Resiquimod significantly decreased mTOR and HIF-1α gene expression in both CLL (p < 0.001and p < 0.001, respectively) and Normal B cells (p = 0.004 and p = 0.001, respectively). Resiquimod may reprogram immunometabolism of malignant B-CLL cells via down-regulation of key glycolytic metabolic actors, mTOR and HIF-1α genes. Accordingly, Resiquimod may be an adjuvant as a therapeutic tool for CLL, which needs to be studied further.Supplementary information: The online version contains supplementary material available at 10.1007/s12288-023-01649-y.","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542076/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41155527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0